EuroQol-5D-3L in Long Covid Patients After Supplementation with EchA Marine®, a Sea Urchin Eggs Extract: a double-blinded, multicentrical randomized trial.

Abstract A double-blinded, multicentrical randomized trial was conducted between September 2021 and December 2022, at 3 hospitals in Buenos Aires. Adult men or non-pregnant adult women between 18-60 years with Long-COVID diagnosed were randomly assigned to the intervention or control group. Patients received EchA Marine®, a dietary supplement based on sea urchin eggs, or matching placebo as follows: 2 daily doses of 3ml for 3 months. The objective was comparing the effectiveness of the dietary supplement with placebo to improve quality of life. The main outcome measures were the values of the dimensions of health of EuroQol 5-Dimension (EQ-5D) questionnaire. Randomization was computer-generated, with allocation concealment by opaque sequentially numbered sealed envelopes. Sequentially numbered identical containers were administered serially to each participant. The randomization results were blinded for the remainder of the research team and for the patients. A total of 50 Long COVID patients were recruited, 22 received placebo and 24 received treatment. Treatment was successful, enhancing quality of patients’ life. Particularly in pain and discomfort (p= 0.005) and mobility (p= 0.013); improving their quality of life and daily activity’s ability. The dietary supplement EchA Marine® is an effective treatment option for Long COVID patients. Trial Registry: www.clinicaltrials.gov; Identifier: NCT05531019.